ganetespib

Known as: 3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole 3h-1,2,4-triazol-3-one, 5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)- 
A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
0102020112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
PURPOSE Treatment options for patients with triple-negative breast cancer (TNBC) are largely limited to systemic chemotherapies… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein critical to tumor growth and… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2013
2013
Heat shock protein 90 (HSP90) is involved in the regulation of diverse biological processes such as cell signaling, proliferation… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in… (More)
Is this relevant?
2012
2012
Mutant KRAS is a feature of more than 25% of non-small cell lung cancers (NSCLC) and represents one of the most prevalent… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling… (More)
Is this relevant?
2011
2011
Systemic chemotherapy using two-drug platinum-based regimens for the treatment of advanced stage non-small cell lung cancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
7500 Background: Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation… (More)
Is this relevant?
2011
2011
There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations… (More)
  • figure 2
  • figure 3
  • table 1
  • figure 4
  • figure 5
Is this relevant?